Original Articles

Metformin Protective Effects in LPS-Induced Alzheimer's Disease Mice Model: NO-cGMP-KATP Pathway Involvement

Abstract

This project has studied the effects of metformin on cognition impairment, depression, hyperalgesia, stress oxidative and neuroinflammation in a rodent Alzheimer's disease (AD) model created via LPS (lipopolysaccharide). For defining possible mechanisms, the NO/cGMP/KATP pathway roleplay was considered.  Mice model was created via LPS treatment. Open field forced swimming and hot plate tests were done. Shuttle-box test and Y-maze test were used to assay Learning-memory. Biochemical assay compromised malondialdehyde (MDA) and TNF-alpha concentration and superoxide dismutase (SOD) activity measurement in hippocampus samples. NO-cGMP-KATP pathway contribution was assessed by its agonists/antagonist pre-treatment, 15 min before metformin (150, 200, 250 mg/kg). Initial latency (IL) was increased by LPS injection while it was reduced by metformin (250 mg), in shuttle-box test. Pretreatment with methylene blue, L-NAME and glibenclamide before metformin augmented IL, although it was diminished by L- arginine and sildenafil pretreatment. Also, metformin increased the LPS induced step through latency (STL) reduction. L-NAME, methylene blue and glibenclamide decreased the STL, but it was increased by L-arginine and sildenafil. In Y-maze test, metformin increased the LPS-induced spontaneous alternation reduction. L-NAME, methylene blue and glibenclamide decreased it. LPS added immobility time in forced swimming trial, whereas it was reduced thru metformin. L-NAME, methylene blue and glibenclamide increased the anti-depressive effect of metformin while it was attenuated via L-arginine, sildenafil and diazoxide. LPS treatment diminished the threshold of pain perception in hot-plate test, while metformin didn’t have any significant effect. Metformin reduced the LPS-induced lipid peroxidation (MDA level). But, L-NAME, methylene blue and glibenclamide worsen the lipid peroxidation, whereas it was improved by L-arginine and sildenafil. Metformin improved LPS-induced reduction in SOD activity. SOD activity was reduced by L-NAME, methylene blue and glibenclamide pre-treatment. LPS enhanced TNF-alpha amount that decreased by metformin. Pre-injection with methylene blue, L-NAME and glibenclamide increased TNF-alpha concentrations while L-arginine, sildenafil and diazoxide reduced it. Conclusions: Metformin can improve learning-memory loss, depression, hyperalgesia, neuroinflammation and oxidative stress produced by LPS and NO/cGMP/KATP pathway maybe has a roleplay. 

1. Janoutová J, Machaczka O, Zatloukalová A, Janout V. Is Alzheimer's disease a type 3 diabetes? A review. Cent Eur J Public Health 2022;30:139-43.
2. Dao L, Choi S, Freeby M. Type 2 diabetes mellitus and cognitive function: understanding the connections. Curr Opin Endocrinol Diabetes Obes 2023; 30:7-13.
3. Gorgich EAC, Parsaie H, Yarmand S, Baharvand F, Sarbishegi M. Long-term administration of metformin ameliorates age-dependent oxidative stress and cognitive function in rats. Behav Brain Res 2021;410:113343.
4. Ortiz MI, Cariño-Cortés R, Castañeda-Hernández G, Medina-Solís CE. Effect of nitric oxide-cyclic GMP-K (+) channel pathway blockers, naloxone and metformin, on the antinociception induced by the diuretic pamabrom. Can J Physiol Pharmacol 2023;101:41-51.
5. Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology 2004;113:427-37.
6. Iwata M, Inoue T, Asai Y, Hori K, Fujiwara M, Matsuo S, et al. The protective role of localized nitric oxide production during inflammation may be mediated by the heme oxygenase-1/carbon monoxide pathway. Biochem Biophys Rep 2020;23:100790.
7. Wallace JL, Miller MJ. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology 2000;119:512-20.
8. Dolatshahi M, Davoudi S, Paridar Y, Naserzadeh R, Ghorbanzadeh B. Pharmacological evidence for the involvement of the opioid system in the antidepressant-like effect of simvastatin in mice: Without tolerance and withdrawal syndrome. Neurosci Lett 2020;714:134578.
9. Dolatshahi M, Hayay Y, Mard-Soltani M, Paridar Y, Nazarinia D. MLR-1023 Improves Cognition Deficiency and Oxidative Stress in Lipopolysaccharide-Induced Mice Model of Alzheimer’s Disease: Role of PPAR-gamma Receptors and NO-cGMP-KATP Channels Pathway. J Adv Immunopharmacol 2024;4:e149170.
10. Pourmansouri Z, Malekkhatabi A, Toolabi M, Akbari M, Shahbazi MA, Rostami A. Anti-Nociceptive Effect of Sufentanil Polymeric Dissolving Microneedle on Male Mice by Hot Plate Technique. Iran Biomed J 2024;28:192-205.
11. Farbood Y, Sarkaki A, Dolatshahi M, Mansouri SMT, Khodadadi A. Ellagic acid protects the brain against 6-hydroxydopamine induced neuroinflammation in a rat model of Parkinson’s disease. Basic Clin Neurosci 2015;6:83-9.
12. Wang Y, Wang M, Fan K, Li T, Yan T, Wu B, et al. Protective effects of Alpinae Oxyphyllae Fructus extracts on lipopolysaccharide-induced animal model of Alzheimer's disease. J Ethnopharmacol 2018;217:98-106.
13. Orzelska-Górka J, Bernat P, Tutka P, Listos J, Kędzierska E, Fidecka S, et al. Modification of NO-cGMP Pathway Differentially Affects Diazepam- and Flunitrazepam-Induced Spatial and Recognition Memory Impairments in Rodents. Neurotox Res 2020;37:1036-46.
14. Dubey H, Gulati K, Ray A. Alzheimer's Disease: A Contextual Link with Nitric Oxide Synthase. Curr Mol Med 2020;20:505-15.
15. Yahil S, Wozniak DF, Yan Z, Mennerick S, Remedi MS. Cognitive deficits and impaired hippocampal long-term potentiation in K(ATP)-induced DEND syndrome. Proc Natl Acad Sci U S A 2021;118:e2109721118.
16. Llansola M, Hernandez-Viadel M, Erceg S, Montoliu C, Felipo V. Increasing the function of the glutamate-nitric oxide-cyclic guanosine monophosphate pathway increases the ability to learn a Y-maze task. J Neurosci Res 2009;87:2351-5.
17. Cabrera-Pastor A, Malaguarnera M, Taoro-Gonzalez L, Llansola M, Felipo V. Extracellular cGMP Modulates Learning Biphasically by Modulating Glycine Receptors, CaMKII and Glutamate-Nitric Oxide-cGMP Pathway. Sci Rep 2016;6:33124.
18. Stefani MR, Nicholson GM, Gold PE. ATP-sensitive potassium channel blockade enhances spontaneous alternation performance in the rat: a potential mechanism for glucose-mediated memory enhancement. Neurosci 1999;93:557-63.
19. Sun J, Qiu L, Zhang H, Zhou Z, Ju L, Yang J. CRHR1 antagonist alleviates LPS-induced depression-like behaviour in mice. BMC Psychiatr 2023; 23:17.
20. Naserzadeh R, Abad N, Ghorbanzadeh B, Dolatshahi M, Mansouri MT. Simvastatin exerts antidepressant-like activity in mouse forced swimming test: Role of NO-cGMP-K(ATP) channels pathway and PPAR-gamma receptors. Pharmacol Biochem Behav 2019; 180:92-100.
21. Yin N, Gao Q, Tao W, Chen J, Bi J, Ding F, et al. Paeoniflorin relieves LPS-induced inflammatory pain in mice by inhibiting NLRP3 inflammasome activation via transient receptor potential vanilloid 1. J Leukoc Biol 2020; 108:229-41.
22. Li DY, Gao SJ, Sun J, Zhang LQ, Wu JY, Song FH, et al. Targeting the nitric oxide/cGMP signaling pathway to treat chronic pain. Neural Regen Res 2023; 18:996-1003.
23. Hajhashemi V, Sadeghi H, Karimi Madab F. Anti-inflammatory and antinociceptive effects of sitagliptin in animal models and possible mechanisms involved in the antinociceptive activity. Korean J Pain 2024; 37:26-33.
24. Schirmbeck GH, Seady M, Fróes FT, Taday J, Da Ré C, Souza JM, et al. Long-term LPS systemic administration leads to memory impairment and disturbance in astrocytic homeostasis. Neurotoxicology 2023; 99:322-31.
25. Park JH, Hwang JW, Lee HJ, Jang GM, Jeong YJ, Cho J, et al. Lomerizine inhibits LPS-mediated neuroinflammation and tau hyperphosphorylation by modulating NLRP3, DYRK1A, and GSK3α/β. Front Immunol 2023;14:1150940.
26. Rapôso C, Luna RL, Nunes AK, Thomé R, Peixoto CA. Role of iNOS-NO-cGMP signaling in modulation of inflammatory and myelination processes. Brain Res Bull 2014; 104:60-73.
27. Qian C, Fan Y, Zong L, Miao C, Ji LL, Wan L, et al. Opening K(ATP) channels induces inflammatory tolerance and prevents chronic pain. Brain Behav Immun 2023; 107:76-86.
28. Tang Z, Shao X, Wu J, Chen H, Zhang A, Xu F, et al. Naloxone Protects against Lipopolysaccharide-Induced Neuroinflammation and Microglial Activation via Inhibiting ATP-Sensitive Potassium Channel. Comput Math Methods Med 2021; 2021:7731528.
29. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000; 71:621s-9.
30. Heidarzadeh M, Amininasab M, Rezayat SM, Mousavi SE. Investigation of Antioxidant and Anti-inflammatory Properties of Berberine Nanomicelles: In vitro and In vivo Studies. Curr Drug Deliv 2024; 21:1273-83.
31. Dowlatshahi K, Ajami M, Pazoki-Toroudi H, Hajimiresmaiel SJ. ATP-dependent potassium channels are implicated in simvastatin pretreatment-induced inhibition of apoptotic cell death after renal ischemia/reperfusion injury. Med J Islam Repub Iran 2015; 29:191.
32. Li M, Li C, Yu H, Cai X, Shen X, Sun X, et al. Lentivirus-mediated interleukin-1β (IL-1β) knock-down in the hippocampus alleviates lipopolysaccharide (LPS)-induced memory deficits and anxiety- and depression-like behaviors in mice. J Neuroinflammation 2017; 14:190.
Files
IssueVol 63 No 1 (2025) QRcode
SectionOriginal Articles
DOI https://doi.org/10.18502/acta.v63i1.18589
Keywords
Metformin Lipopolysaccharides (LPS) Cognition Oxidative stress Depression Hyperalgesia Neuroinflammation Mice

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Dolatshahi M, Khorsandinezhad A, Ghorbanzadeh B, Paridar Y, Nazarinia D. Metformin Protective Effects in LPS-Induced Alzheimer’s Disease Mice Model: NO-cGMP-KATP Pathway Involvement. Acta Med Iran. 2025;63(1):7-18.